Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($1.61), $0.60 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $131.38 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.